FibroBiologics Future Growth
Future criteria checks 0/6
FibroBiologics's earnings are forecast to decline at 25.1% per annum while its annual revenue is expected to grow at 94.1% per year. EPS is expected to decline by 10.8% per annum.
Key information
-25.1%
Earnings growth rate
-10.8%
EPS growth rate
| Biotechs earnings growth | 43.3% |
| Revenue growth rate | 94.1% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 14 Nov 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | N/A | -23 | -25 | -24 | 4 |
| 12/31/2025 | N/A | -15 | -16 | -15 | 4 |
| 12/31/2024 | N/A | -12 | -13 | -14 | 4 |
| 9/30/2024 | N/A | -18 | -11 | -10 | N/A |
| 6/30/2024 | N/A | -19 | -9 | -9 | N/A |
| 3/31/2024 | N/A | -23 | -9 | -9 | N/A |
| 12/31/2023 | N/A | -19 | -7 | -6 | N/A |
| 9/30/2023 | N/A | -11 | -6 | -6 | N/A |
| 6/30/2023 | N/A | -10 | -6 | -6 | N/A |
| 3/31/2023 | N/A | -9 | -5 | -5 | N/A |
| 12/31/2022 | N/A | -5 | -4 | -4 | N/A |
| 12/31/2021 | N/A | -2 | -1 | -1 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SG0 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: SG0 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: SG0 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: SG0 is forecast to have no revenue next year.
High Growth Revenue: SG0 is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if SG0's Return on Equity is forecast to be high in 3 years time